ESOU programme

Friday, 17 January

08.30 - 08.40 Welcome
M. Babjuk, Prague (CZ)
M. Brausi, Modena (IT)

08.40 - 09.00 Opening address

09.00 - 11.00 Prostate cancer I: Screening, diagnosis, staging and treatment
Chairs: M. Brausi, Modena (IT)
V. Ravery, Paris (FR)

09.00 - 09.20 Prostate cancer screening: Why screening programme should not be adopted in > 65
A. Heidenreich, Aachen (DE)

09.20 - 09.30 Discussion

09.30 - 09.45 Diagnostic strategies for early detection of PCa
A. Govorov, Moscow (RU)

09.45 - 10.45 Debate: Prostate biopsy and pathological evaluation—How to achieve maximum information
09.45 - 10.00 Is it time to trash TRUS biopsy?
B. Djavan, Vienna (AT)
10.00 - 10.15 The indication for prostate biopsy in 2014: MRI directed biopsy, is it becoming a standard?
A. Villers, Lille (FR)
10.15 - 10.30 How reliable is the pathological examination to make clinical decisions?
R. Montironi, Ancona (IT)
10.30 - 10.45 The role of tissue biomarkers to predict prognosis
Z. Culig, Innsbruck (AT)

10.45 - 11.00 Discussion

11.00 - 11.15 Coffee break

11.15 - 12.15 Active treatment vs active surveillance for low risk PCa in young men
Chairs: M. Emberton, London (GB)
M. Wirth, Dresden (DE)

11.15 - 11.30 Robotic RP (video)
B. Rocco, Milan (IT)

11.30 - 11.45 Focal therapy
M. Emberton, London (GB)

11.45 - 12.00 Active surveillance
L. Klotz, Toronto (CA)

12.00 - 12.15 Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.15 - 13.45</td>
<td><strong>Renal Cancer: Localised</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: P. Mulders, Nijmegen (NL)</td>
</tr>
<tr>
<td></td>
<td>H. Ozen, Ankara (TR)</td>
</tr>
<tr>
<td>12.15 - 12.30</td>
<td><strong>Can we predict histology of renal tumors by imaging and macroscopic appearance? Clinical consequences</strong></td>
</tr>
<tr>
<td></td>
<td>M. Hora, Pilsen (CZ)</td>
</tr>
<tr>
<td>12.30 - 12.45</td>
<td><strong>New pathological classification: Grading</strong></td>
</tr>
<tr>
<td></td>
<td>F. Algaba, Barcelona (ES)</td>
</tr>
<tr>
<td>12.45 - 13.00</td>
<td><strong>Debate: The best treatment for renal masses &gt; 3 cm in the elderly (&gt;75) patients</strong></td>
</tr>
<tr>
<td>12.45 - 13.00</td>
<td>Active surveillance: Has it a role?</td>
</tr>
<tr>
<td></td>
<td>A. Volpe, Novara (IT)</td>
</tr>
<tr>
<td>13.00 - 13.15</td>
<td>Ablation therapy: Pro</td>
</tr>
<tr>
<td></td>
<td>R. Illing, London (GB)</td>
</tr>
<tr>
<td>13.15 - 13.30</td>
<td>Surgery: Still the best?</td>
</tr>
<tr>
<td></td>
<td>G. Janetscheck, Salzburg (AT)</td>
</tr>
<tr>
<td>13.30 - 13.45</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>13.45 - 14.45</td>
<td><strong>Lunch</strong></td>
</tr>
<tr>
<td>14.45 - 15.15</td>
<td><strong>Penile cancer</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: F. Algaba, Barcelona (ES)</td>
</tr>
<tr>
<td></td>
<td>A. Govorov, Moscow (RU)</td>
</tr>
<tr>
<td>14.45 - 15.00</td>
<td><strong>Pre-Malignant lesions: Incidence and classifications</strong></td>
</tr>
<tr>
<td></td>
<td>F. Algaba, Barcelona (ES)</td>
</tr>
<tr>
<td>15.00 - 15.15</td>
<td><strong>Mini-invasive therapies for clinically localised penile tumours</strong></td>
</tr>
<tr>
<td></td>
<td>C. Protzel, Rostock (DE)</td>
</tr>
<tr>
<td>15.15 - 15.15</td>
<td><strong>Urothelial cancer I: Non muscle invasive</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: V. Altieri, Salerno (IT)</td>
</tr>
<tr>
<td></td>
<td>J. Palou, Barcelona (ES)</td>
</tr>
<tr>
<td>15.15 - 15.35</td>
<td><strong>Circulating tumor cells in bladder cancer: A new marker?</strong></td>
</tr>
<tr>
<td></td>
<td>A. Alcaraz, Barcelona (ES)</td>
</tr>
<tr>
<td>15.35 - 16.15</td>
<td><strong>Debate: Standard TUR and cytology vs TUR and new technologies</strong></td>
</tr>
<tr>
<td></td>
<td>Standard TUR: T. O’Brien, London (GB)</td>
</tr>
<tr>
<td></td>
<td>New technologies: F. Witjes, Nijmegen (NL)</td>
</tr>
<tr>
<td>16.15 - 16.35</td>
<td><strong>Coffee break</strong></td>
</tr>
<tr>
<td>16.35 - 16.45</td>
<td><strong>Bladder Cancer Prevention Program: An international initiative by Maurizio Brausi</strong></td>
</tr>
<tr>
<td></td>
<td>M. Brausi, Modena (IT)</td>
</tr>
<tr>
<td>16.45 - 18.15</td>
<td><strong>Urothelial cancer II: Non muscle invasive</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: V. Altieri, Salerno (IT)</td>
</tr>
<tr>
<td></td>
<td>J. Palou, Barcelona (ES)</td>
</tr>
</tbody>
</table>
Friday, 17 January – continued

16.45 – 17.15  | Debate: Treatment of intermediate risk patients: Chemotherapy vs BCG
16.45 – 17.00  | Chemo is appropriate: P-U. Malmström, Uppsala (SE)
17.00 – 17.15  | BCG is the best: L. Martinez Pineiro, Madrid (ES)

17.15 – 17.30  | Discussion

17.30 – 17.45  | BCG in the elderly: Still a good choice?
               | M. Colombel, Lyon (FR)

17.45 – 18.00  | Discussion

18.00 – 18.15  | Best NMIBC papers
               | G. Giannarini, Berne (CH)
Saturday, 18 January

08.30 – 10.30 Prostate cancer II: Localised
Chairs:  B. Djavan, Vienna (AT)
        G. Janetschek, Salzburg (AT)

08.30 – 08.50 Treatment algorithm in high risk Pca
P-A. Abrahamsson, Malmö (SE)

08.50 – 10.10 Debate: High risk clinically localised Pca
08.50 – 09.10 Radical prostatectomy: How I do it step by step (Video)
H. Van Poppel, Leuven (BE)
09.10 – 09.30 Radiotherapy is better: New technologies (Cyberknife, Protons..)
A. Bossi, Villejuif (FR)
09.30 – 09.50 Robotic radical prostatectomy and extended lymphadenectomy for cT3 Pca: Surgical technique and outcomes (Video and lecture)
P. Wiklund, Stockholm (SE)
09.50 – 10.10 Laparoscopic RP for cT3: Same results but less expensive?
J. Rassweiler, Heilbronn (DE)

10.10 – 10.30 Discussion

10.30 – 11.30 Testicular cancer
Chairs:  P. Albers, Düsseldorf (DE)
        B. Rocco, Milan (IT)

10.30 – 10.45 Standard treatment and new messages in the management of Stage I disease
T. Tandsted, Trondheim (N)

10.45 – 11.00 New messages in intermediate and poor risk disease
A. Horwich, Sutton (GB)

11.00 – 11.15 Surgical approaches in complex cases
V. Matveev, Moscow (RU)

11.15 – 11.30 Discussion

11.30 – 11.45 Coffee break

11.45 – 13.45 Urothelial cancer III: Muscle invasive and advanced disease
Chairs:  W. Artibani, Verona (IT)
        G.N. Thalmann, Berne (CH)

11.45 – 12.00 Radical cystectomy and orthotopic neobladder in women: Long term results and QoL
A. Stenzl, Tübingen (DE)

12.00 – 12.30 Debate: Prostate sparing radical cystectomy
Defending:  M. Brausi, Modena (IT)
Challenging:  M. Babjuk, Prague (CZ)

12.30 – 12.45 Discussion
Saturday, 18 January – continued

12.45 – 13.25  Debate: Therapeutic strategies in elderly (>75) and frail patients with muscle-invasive bladder cancer
12.45 – 12.55  Geriatric evaluation (definition of frail and clinical impact)
                F. Montorsi, Milan (IT)
12.55 – 13.05  Surgery
                P. Albers, Düsseldorf (DE)
13.05 – 13.15  Radio-chemotherapy
                H. Van Der Poel, Amsterdam (NL)
13.15 – 13.25  Local control and best supportive care
                L. Türkeri, Istanbul (TR)

13.25 – 13.45  Discussion

14.00 – 16.00  STEPS (Session To Evaluate Progress) programme
                (closed programme: participation by invitation only)
                Led by Prof. M. Brausi, Modena (IT)

                • Prostate Cancer table Chair: L. Klotz, Toronto (CA)
                • Bladder Cancer table Chair: A. Stenzl, Tübingen (DE)
                • Kidney Cancer table Chair: P. Mulders, Nijmegen (NL)
Sunday, 19 January

09.00 – 10.00 | Disaster management and prevention in uro-oncological surgery (open, robotic and lap)
Chairs: T. Hanus, Prague (CZ)
        H. Van Poppel, Leuven (BE)

09.00 – 09.20 | Intra-OP
V. Pansadoro, Rome (IT)

09.20 – 09.40 | Late
V. Pansadoro, Rome (IT)

09.40 – 10.00 | Case Discussion
Case presenter: M. Babjuk, Prague (CZ)
Panel: A. Stenzl, Tübingen (DE)
       W. Artibani, Verona (IT)
       V. Pansadoro, Rome (IT)
       P-A. Abrahamson, Malmö (SE)

10.00 – 11.15 | Cytoreductive surgery in metastatic disease
Chair: G. Mickisch, Bremen (DE)
       F. Montorsi, Milan (IT)

10.00 – 10.15 | Rationale
J. Catto, Sheffield (GB)

10.15 – 10.30 | Kidney
H. Van Poppel, Leuven (BE)

10.30 – 10.45 | Bladder
J. Palou, Barcelona (ES)

10.45 – 11.00 | Prostate
A. Heidenreich, Aachen (DE)

11.00 – 11.15 | Discussion

11.15 – 11.45 | Coffee break

11.45 – 12.35 | Muscle invasive Bladder Cancer
Chairs: S. Brewster, Oxford (GB)
       L. Jarolim, Prague (CZ)

11.45 – 12.05 | Standardising complications reporting after radical cystectomy
G. Thalmann, Berne (CH)

12.05 – 12.25 | Functional outcomes of orthotopic reservoirs following radical cystectomy. Searching the truth
W. Artibani, Verona (IT)

12.25 – 12.35 | Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12.35 - 13.45 | **Prostate Cancer III: Advanced and metastatic**  
Chair: A. Heidenreich, Aachen (DE)  
P. Albers, Düsseldorf (DE) |
| 12.35 - 12.50 | **Intermittent vs continuous ADT: Still controversial?**  
P.A. Abrahamsson, Malmö (SE) |
| 12.50 - 13.05 | **Local treatment of oligometastatic disease: Lymphadenectomy**  
A. Briganti, Milan (IT) |
| 13.05 - 13.20 | **Bone metastases**  
S. Joniau, Leuven (BE) |
| 13.20 - 13.35 | **When should we start treatment in CRPC patients?**  
P. Albers, Düsseldorf (DE) |
| 13.35 - 13.45 | **Discussion** |
| 13.45      | **End of the ESOU meeting**  
M. Babjuk, Prague (CZ)  
M. Brausi, Modena (IT) |